Hepatitis C virus genotype 4 and response to combination therapy with interferon-α2b plus ribavirin

被引：4
|
作者：
Bruno, S [1 ]
Crosignani, A
Pinzello, GB
机构：
[1] S Paolo Univ Milan, I-20142 Milan, Italy
[2] Crespi Niguarda Hosp Milan, Liver Unit, I-20100 Milan, Italy
来源：
ANNALS OF INTERNAL MEDICINE | 2000年 / 133卷 / 11期
关键词：
D O I：
10.7326/0003-4819-133-11-200012050-00025
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：922 / 923
页数：2
相关论文
共 50 条
  • [21] Interferon-α-2b plus ribavirin -: A review of its use in the management of chronic hepatitis C
    Scott, LJ
    Perry, CM
    DRUGS, 2002, 62 (03) : 507 - 556
  • [22] Catatonia Associated with Pegylated Interferon-α 2b and Ribavirin for Hepatitis C
    Quinn, Davin
    Kuchler, Elizabeth
    Deming, Paulina
    Arora, Sanjeev
    PSYCHOSOMATICS, 2012, 53 (04) : 400 - 401
  • [23] Evaluation of Temporal Virological Responses to Interferon-α-2b plus Ribavirin among Genotype 3a Hepatitis C Virus-Infected Patients
    Raza, Abida
    Ovais, Muhammad
    Aziz, Hafsa
    Anwar, Asim
    Irfan, Javaid
    Ahmad, Irshad
    Mukhtar, Muhammad
    INTERVIROLOGY, 2017, 60 (03) : 75 - 81
  • [24] Dose comparison study of pegylated interferon-α-2b plus ribavirin in naive Japanese patients with hepatitis C virus genotype 2: A randomized clinical trial
    Kawaoka, Tomokazu
    Kawakami, Yoshiiku
    Tsuji, Keiji
    Ito, Hiroyuki
    Kitamoto, Mikiya
    Aimitsu, Shiomi
    Kawakami, Hiroiku
    Jeong, Soo Cheol
    Imamura, Michio
    Aikata, Hiroshi
    Takahashi, Shoichi
    Chayama, Kazuaki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 (03) : 366 - 371
  • [25] Pegylated interferon-α2b plus ribavirin therapy in patients with hepatitis C and psychiatric disorders: results of a cohort study
    Lang, Jean-Philippe
    Melin, Pascal
    Ouzan, Denis
    Rotily, Michel
    Fontanges, Thierry
    Marcellin, Patrick
    Chousterman, Michel
    Cacoub, Patrice
    ANTIVIRAL THERAPY, 2010, 15 (04) : 599 - 606
  • [26] Diabetes mellitus reduces the therapeutic effectiveness of interferon-α2b plus ribavirin therapy in patients with chronic hepatitis C
    Konishi, Ichiro
    Horiike, Norio
    Hiasa, Yoichi
    Tokumoto, Yoshio
    Mashiba, Toshie
    Michitaka, Kojiro
    Miyake, Yasuyuki
    Nonaka, Suguru
    Joukou, Kouji
    Matsuura, Bunzo
    Onji, Morikazu
    HEPATOLOGY RESEARCH, 2007, 37 (05) : 331 - 336
  • [27] Effect of treatment with interferon α-2b and ribavirin in patients infected with genotype 2 hepatitis C virus
    Nagase, Yoshihiko
    Yotsuyanagi, Hiroshi
    Okuse, Chiaki
    Yasuda, Kiyomi
    Kato, Tomohiro
    Koike, Kazuhiko
    Suzuki, Michihiro
    Nishioka, Kusuki
    Iino, Shiro
    Itoh, Fumio
    HEPATOLOGY RESEARCH, 2008, 38 (03) : 252 - 258
  • [28] Efficacy and safety of combination therapy with interferon-α2b and ribavirin for chronic hepatitis C in HIV-infected patients
    Landau, A
    Batisse, D
    Van Huyen, JPD
    Piketty, C
    Bloch, F
    Pialoux, G
    Belec, L
    Petite, JP
    Weiss, L
    Kazatchkine, M
    AIDS, 2000, 14 (07) : 839 - 844
  • [29] Ribavirin concentration in the later stages of 48 week pegylated interferon-α2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response
    Furusyo, Norihiro
    Murata, Masayuki
    Ogawa, Eiichi
    Toyoda, Kazuhiro
    Ihara, Takeshi
    Ikezaki, Hiroaki
    Hayashi, Takeo
    Koga, Tsunehisa
    Kainuma, Mosaburo
    Hayashi, Jun
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (05) : 1127 - 1139
  • [30] Chronic hepatitis C in HIV-coinfected patients:: Feasibility and efficacy of interferon-α2b and ribavirin combination therapy
    Nasti, G
    di Gennaro, G
    Rizzardini, G
    Cadorin, L
    Tirelli, U
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2001, 26 (03) : 299 - 300
12345